Conduit Pharmaceuticals Inc. Files 8-K on Shareholder Vote
Ticker: CDTTW · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing-update
TL;DR
Conduit Pharma (formerly Murphy Canyon) filed an 8-K on Jan 13th for a shareholder vote.
AI Summary
Conduit Pharmaceuticals Inc. filed an 8-K on January 14, 2025, reporting on matters submitted to a vote of security holders on January 13, 2025. The company, formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021, is incorporated in Delaware and headquartered in Naples, Florida.
Why It Matters
This filing indicates Conduit Pharmaceuticals Inc. is proceeding with corporate actions requiring shareholder approval, which could impact the company's future direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- January 13, 2025 (date) — Date of earliest event reported
- January 14, 2025 (date) — Filing date
- November 30, 2021 (date) — Date of name change
FAQ
What specific matters were submitted to a vote of Conduit Pharmaceuticals Inc. security holders?
The filing states that matters were submitted to a vote of security holders on January 13, 2025, but the specific details of these matters are not provided in this excerpt.
When did Conduit Pharmaceuticals Inc. change its name from Murphy Canyon Acquisition Corp.?
Conduit Pharmaceuticals Inc. changed its name from Murphy Canyon Acquisition Corp. on November 30, 2021.
What is the primary business of Conduit Pharmaceuticals Inc. according to the SIC code?
According to its Standard Industrial Classification (SIC) code 2834, Conduit Pharmaceuticals Inc. is involved in Pharmaceutical Preparations.
Where is Conduit Pharmaceuticals Inc. headquartered?
Conduit Pharmaceuticals Inc. is headquartered in Naples, Florida, with its business address at 4851 Tamiami Trail North, Suite 200.
What is the SEC file number for Conduit Pharmaceuticals Inc.?
The SEC file number for Conduit Pharmaceuticals Inc. is 001-41245.
Filing Stats: 746 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-14 16:45:22
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 45KB
- 0001493152-25-002176.txt ( ) — 268KB
- cdt-20250113.xsd (EX-101.SCH) — 4KB
- cdt-20250113_def.xml (EX-101.DEF) — 29KB
- cdt-20250113_lab.xml (EX-101.LAB) — 36KB
- cdt-20250113_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 14, 2025 CONDUIT PHARMACEUTICALS INC. By: /s/ David Tapolczay Name: David Tapolczay Title: Chief Executive Officer